The stock is likely to react positively to the strong Med Tech growth and raised guidance, which indicates the company's strategic transformation is gaining traction. However, traders should monitor the impact of tariffs on gross margins and the leadership transition, as the CEO retirement could introduce near-term uncertainty despite the strong operational performance.
Price Chart
Executive Summary
AngioDynamics reported strong fiscal Q3 2026 results with 8.9% YoY revenue growth and a 19% increase in Med Tech sales, driven by Auryon and NanoKnife. The company raised full-year guidance for net sales and Adjusted EBITDA for the third consecutive quarter, signaling sustained profitable growth despite a slight YoY decline in gross margin due to tariffs. CEO Jim Clemmer will retire during fiscal 2027 upon the appointment of a successor.
Key Financial Metrics
Key Facts
- Q3 revenue of $78.4M, up 8.9% YoY (consensus: $76.8M), beating by 2.1%
- Med Tech sales grew 19.0% YoY to $37.3M, sixth consecutive quarter of double-digit growth
- Adjusted EBITDA of $1.8M, up from $1.3M in prior year quarter
- Full-year 2026 guidance raised: Net sales to $313.5-$315.5M (up from $312-$314M), Adjusted EBITDA to $10.0-$12.0M (up from $8.0-$10.0M)
- Gross margin was 52.9%, down 110 bps YoY due to tariffs and inflation
- CEO Jim Clemmer to retire in fiscal 2027; board has initiated a search for successor
Financial Impact
$78.4M revenue (8.9% YoY growth), $37.3M Med Tech sales (19% YoY growth), raised full-year guidance
Risk Factors
- Gross margin declined 110 bps YoY to 52.9% due to tariffs and inflation, which could pressure profitability if sustained
- CEO Jim Clemmer's planned retirement in fiscal 2027 introduces leadership transition risk, which could affect strategic continuity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-012891 |
| Document: ef20069681_8k.htm | 0001140361-26-012891 |
| Document: ef20069681_ex99-2.htm | 0001140361-26-012891 |
| Document: 0001140361-26-012891-index-headers.html | 0001140361-26-012891 |
| Document: 0001140361-26-012891-index.html | 0001140361-26-012891 |
| Document: 0001140361-26-012891.txt | 0001140361-26-012891 |
| 8-K Data (Synthetic) | 0001140361-26-012891 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 19d ago | DEFA14A | $11.23 $11.58 | ▲ +3.12% | ▲ +3.39% | $12.26 (+9.17%) |
Oct 8, 2026 19d ago | DEF 14A | $11.23 $11.58 | ▲ +3.12% | ▲ +3.39% | $12.26 (+9.17%) |
Oct 8, 2026 19d ago | 8-K | $11.23 $11.58 | ▲ +3.12% | ▲ +3.39% | $12.26 (+9.17%) |
Oct 8, 2026 19d ago | 8-K | $11.23 $11.58 | ▲ +3.12% | ▲ +3.39% | $12.26 (+9.17%) |
Jul 14, 2026 15w ago | 8-K | $13.00 $13.71 | ▲ +5.46% | ▲ +6.76% | $12.26 (−5.69%) |
Apr 2, 2026 29w ago | 8-K | $10.31 $9.80 | ▼ −4.95% | ▼ −8.57% | $12.26 (+18.91%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers